Reports

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

MEDICAL OPTIONS - Respirology

Evolution in Management of Pulmonary Arterial Hypertension (PAH)

March 2016

Targeting of the Prostacyclin Pathway in PAH Editorial ReviewWritten by: Theodore Bosworth Steeve Provencher, MD, MPH, FRCPCDirector, Pulmonary Hypertension ProgramProfessor, Université LavalQuebec City, Quebec For the treatment...

PHYSICIAN PERSPECTIVE - Get With the Protocol - A Regional Perspective on the Evidence and Resulting Changes

Rouge Valley Health System

August 2015

Guest Editor: Saleem Kassam, MD Department of Cardiology Rouge Valley Health System Toronto, Ontario   Introduction In patients presenting with an acute coronary syndrome (ACS), early initiation of oral antiplatelet therapy is...

PHYSICIAN PERSPECTIVE - Get With the Protocol - A Regional Perspective on the Evidence and Resulting Changes

St. Mary’s General Hospital

March 2015

Guest Editor: Hahn Hoe Kim, MD, FRCP(C) Department of CardiologySt. Mary’s General HospitalKitchener, Ontario   Introduction In patients presenting with an acute coronary syndrome (ACS), early initiation of oral antiplatelet...

PHYSICIAN PERSPECTIVE - Get With the Protocol - NSTEMI Decision-Tree Accelerates Introduction of Evidence-Based Therapies

University of Ottawa Heart Institute

February 2015

Guest Editor: Michel Le May, MD, FRCPCDirector, Coronary Care Unit, and University of Ottawa Heart Institute Regional STEMI ProgramProfessor of MedicineUniversity of Ottawa Heart InstituteOttawa, Ontario   Introduction In patients...

PRIORITY PRESS - American Heart Association (AHA) Scientific Sessions 2014

Lower Is Better: New Data Confirm the LDL Hypothesis as New Options Are Identified for Improved Control

Chicago, Illinois / November 15-19, 2014

Chicago - New evidence of a cardiovascular (CV) benefit from lipid-lowering therapy with a non-statin has extended the lipid hypothesis, expanding opportunities for risk reduction. One of the trials presented at the 2014 Scientific Sessions...

PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the American Heart Association (AHA) 2014 Scientific Sessions

IMPROVE-IT: Reaffirmation of Lipid Hypothesis By Non-Statin Ezetimibe in High-Risk Population

Chicago, Illinois / November 15-19, 2014

Guest Editor: Dr. Paul W. Armstrong, MD, FCAHS, FRSCDistinguished University ProfessorMazankowski Alberta Heart InstituteUniversity of AlbertaEdmonton, Alberta Dr. Armstrong served on the Steering Committee of IMPROVE-IT and was one of...

PRIORITY PRESS - Canadian Cardiovascular Congress (CCC)

The LDL-C Treatment Gap Expected to Be Essentially Closed with New Lipid-Lowering Agents

Vancouver, BC / October 25-28, 2014

Vancouver - Lipid-lowering therapies now in late stages of development are expected to bring the majority of patients to guideline-recommended treatment goals regardless of the reason why they are unable to reach their goal on current...

MEDICAL FRONTIERS - 36th Annual Congress of the European Society of Cardiology (ESC)

More Aggressive Strategies for Early Detection of Pulmonary Hypertension Supported by Outcome Trials

Barcelona, Spain / August 30-September 3, 2014

Barcelona - Pulmonary arterial hypertension (PAH) should be treated earlier and more aggressively, according to a new analysis of clinical trials with mortality and morbidity endpoints. By demonstrating that outcomes are better when...

PRIORITY PRESS - 36th Annual Congress of the European Society of Cardiology (ESC)

New Options Emerging for Cholesterol Lowering in Patients Not Adequately Controlled on Statins

Barcelona, Spain / August 30-September 3, 2014

Barcelona - A new therapeutic drug class can reduce low-density lipoprotein cholesterol (LDL-C) levels by more than 60% in patients on maximally tolerated statins, according to a series of phase 3 trials conducted in high-risk patient...

PAGE 1 OF 27   1 2 3 4 5 6 7 8 9 10 ...